Frizzled receptor antibodies for treatment of cancer

Patent metadata

Field	Value
Publication number	US-10465004-B2
Application number	US-201515109173-A
Country	US
Kind code	B2
Filing date	Jan 1, 2015
Priority date	Jan 2, 2014
Publication date	Nov 5, 2019
Grant date	Nov 5, 2019

Abstract

The invention provides antibodies or an antigen-binding portion thereof, which recognize the human Frizzled 7 receptor. Further, the invention provides methods of using these antibodies for the treatment cancer in a subject.

First claim

What is claimed is:

1. A method for treating a tumor characterized by elevated expression of a Frizzled7 receptor in a subject, said method comprising the step of administering a therapeutically effective dose of an isolated antibody or antigen-binding portion thereof that binds to a Frizzled7 receptor, wherein the antibody binds to the cytoplasmic portion of said receptor and wherein the antibody has complementarity determining regions (CDRs) of the antibody produced by the hybridoma cell line 288-1 deposited in the American Type Culture Collection, Manassas, Va., USA, under the Registration Number PTA-123746; or the antibody produced by the hybridoma cell line 288-5 deposited in the American Type Culture Collection, Manassas, Va., USA, under the Registration Number PTA-123744.

2. The method of claim 1 , wherein the isolated antibody or antigen-binding portion thereof is coupled to a cytotoxic moiety.

3. The method of claim 1 , wherein the isolated antibody is recombinant antibody.

4. The method of claim 3 , wherein the isolated antibody is a single chain antibody, Fab, Fv, diabody or triabody.

5. The method of claim 1 , wherein said antibody is humanized, chimeric or chimeric/humanized.

6. The method of claim 1 , wherein said tumor is Wilm's tumor.

7. The method of claim 1 , wherein said tumor is comprised of melanoma cells.

8. The method of claim 1 , wherein the method further comprises the step of administering a chemotherapy antibody.

9. The method of claim 1 , wherein the method comprises the step of administering a second antibody or antigen-binding portion thereof.

10. The method of claim 1 , wherein the isolated antibody is a whole antibody.

11. The method of claim 1 , wherein the isolated antibody is IgG1, IgG2, IgG3 or IgG4.

12. The method of claim 1 , wherein the isolated antibody induces antibody-dependent cellular cytotoxicity (ADCC).

Assignees

• Tel Hashomer Medical Res Infrastructure & Services Ltd
• Univ Ramot

Inventors

• Dekel Benjamin
• Pode-Shakked Naomi
• Harai-Steinberg Orit
• Mark-Danieli Michal
• Vax Einav

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• C07K16/30

  from tumour cells · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• C07K2317/34

  Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title